Yıl: 2023 Cilt: 33 Sayı: 2 Sayfa Aralığı: 81 - 87 Metin Dili: İngilizce DOI: 10.5336/jcog.2022-94609 İndeks Tarihi: 05-07-2023

Variants of Fumarate Hydratase Gene in Uterine Disorders: A Clinical Trial

Öz:
Objective: The dysregulation of metabolism is a hallmark of cancer. Enzymes of tricarboxylic acid (TCA) cycle have a key role in pathogenesis of carcinogenesis as oncometabolits. The variants in fumarate hydratase (FH) gene have been linked to sporadic tumors and familial tumor propensity. To asses the prevalence of variants in the FH gene in endometrial carcinoma (EC) and uterine leiomyo mas (UL). Material and Methods: This prospective study included 58 patients with EC and 44 with UL. The FH gene variants were analyzed in the DNA samples collected from peripheral circulation. All exons of the FH gene were replicated by polymerase chain reaction utilizingspecific primers including intron-exon boundaries and than was sequenced with Sanger method.Results: Only two variants were detected in two different pa- tients. The c.927G>A (p.Pro309Pro) and c.63C>T (p.Ala21Ala) variants were observed in patients with UL, EC respectively. c.927G >A (p.Pro309=) and c.63C>T (p.Ala21=) are rare variants inside the overall population with allele frequency ranges of 0.02428, 0.0 00014 re- spectively. Conclusion: The contribution of variants in genes encoding the TCA cycle enzymes in tumor cells has provided understanding fundamental role on metabolic alterations in carcinogenesis. Further studies are needed to discover the novel tumor mutations and identify ap- propriate treatment.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Hanahan D, Weinberg RA. Hallmarks o f cancer: the next generation. Cell. 2011;144(5):646-74. [Crossref] [PubMed]
  • 2. fuhler GM, Eppinga H, Peppelenbosch MP. fumarates and cancer. Trends Mol Med. 2017;23(1):3-5. [Crossref] [PubMed]
  • 3. Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, et al. Inhibition o f α-KG-depen- dent histone and DNA demethylases by fumarate and succinate that are ac- cumulated in mutations o f fH and SDH tumor suppressors. Genes Dev. 2012;26(12):1326-38. Erratum in: Genes Dev. 2015;29(8):887. [Crossref] [PubMed] [PMC]
  • 4. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al; Multiple Leiomyoma Consortium. Germline mutations in fH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30(4):406-10. [Crossref] [PubMed]
  • 5. Linehan WM, Rouault TA. Molecular pathways: fumarate hydratase-deficient kidney cancer--targeting the Warburg e ffect in cancer. Clin Cancer Res. 2013;19(13):3345-52. [Crossref] [PubMed] [PMC]
  • 6. Gunnala v, Pereira N, Irani M, Lilienthal D, Pirog EC, Soslow R, et al. Novel fumarate hydratase mutation in siblings with early onset uterine leiomyomas and hereditary leiomyomatosis and renal cell cancer syndrome. Int J Gynecol Pathol. 2018;37(3):256-61. [Crossref] [PubMed] [PMC]
  • 7. frey MK, Worley MJ Jr, Heyman KP, Caputo TA. A case report of hereditary leiomyomatosis and renal cell cancer. Am J Obstet Gynecol. 2010;202(6):e8- 9. [Crossref] [PubMed]
  • 8. Smit DL, Mensenkamp AR, Badeloe S, Breuning MH, Simon ME, van Spaen- donck KY, et al. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis. Clin Genet. 2011;79(1):49-59. [Crossref] [PubMed]
  • 9. Sung H, ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mor- tality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. [Crossref] [PubMed]
  • 10. Yen TT, Wang TL, fader AN, Shih IM, Gaillard S. Molecular classification and emerging targeted therapy in endometrial cancer. Int J Gynecol Pathol. 2020;39(1):26-35. [Crossref] [PubMed] [PMC]
  • 11. Sparic R, Mirkovic L, Malvasi A, Tinelli A. Epidemiology of uterine myomas: a review. Int J fertil Steril. 2016;9(4):424-35. [PubMed] [PMC]
  • 12. Wheeler KC, Warr DJ, Warsetsky SI, Barmat LI. Novel fumarate hydratase mutation in a family with atypical uterine leiomyomas and hereditary leiomy- omatosis and renal cell cancer. fertil Steril. 2016;105(1):144-8. [Crossref] [PubMed]
  • 13. Zhao Z, Wang W, You Y, Zhu L, feng f. Novel fH mutation associated with multiple uterine leiomyomas in Chinese siblings. Mol Genet Genomic Med. 2020;8(1):e1068. [Crossref] [PubMed] [PMC]
  • 14. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-14. [Crossref] [PubMed]
  • 15. Gonçalves E, Sciacovelli M, Costa ASH, Tran MGB, Johnson TI, Machado D, et al. Post-translational regulation of metabolism in fumarate hydratase deficient cancer cells. Metab Eng. 2018;45:149-57. [Crossref] [PubMed] [PMC]
  • 16. Pezzuto A, Carico E. Role o f HIf-1 in cancer progression: novel insights. a review. Curr Mol Med. 2018;18(6):343-51. [Crossref] [PubMed]
  • 17. Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013;27(8):836-52. [Cross- ref] [PubMed] [PMC]
  • 18. Sciacovelli M, frezza C. Oncometabolites: unconventional triggers of onco- genic signalling cascades. free Radic Biol Med. 2016;100:175-81. [Cross- ref] [PubMed] [PMC]
  • 19. Schaefer IM, Hornick JL, Bovée J vMG. The role o f metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms. Lab Invest. 2018;98(4):414-26. [Crossref] [PubMed]
  • 20. Aissani B, Zhang K, Mensenkamp AR, Menko fH, Wiener HW. fine map- ping of the uterine leiomyoma locus on 1q43 close to a lncRNA in the RGS7- fH interval. Endocr Relat Cancer. 2015;22(4):633-43. [Crossref] [PubMed] [PMC]
  • 21. Miettinen M, felisiak-Golabek A, Wasag B, Chmara M, Wang Z, Butzow R, et al. fumarase-deficient uterine leiomyomas: an immunohistochemical, mo- lecular genetic, and clinicopathologic study o f 86 cases. Am J Surg Pathol. 2016;40(12):1661-9. [Crossref] [PubMed] [PMC]
  • 22. Harrison WJ, Andrici J, Maclean f, Madadi-Ghahan R, farzin M, Sioson L, et al. fumarate hydratase-deficient uterine leiomyomas occur in both the syn- dromic and sporadic settings. Am J Surg Pathol. 2016;40(5):599-607.[Cross- ref] [PubMed] [PMC]
  • 23. Talhouk A, McAlpine JN. New classi fication of endometrial cancers: the de- velopment and potential applications o f genomic-based classification in re- search and clinical care. Gynecol Oncol Res Pract. 2016;3:14. [Crossref] [PubMed] [PMC]
  • 24. Ylisaukko-oja SK, Cybulski C, Lehtonen R, Kiuru M, Matyjasik J, Szyma-ska A, et al. Germline fumarate hydratase mutations in patients with ovarian mu- cinous cystadenoma. Eur J Hum Genet. 2006;14(7):880-3. [Crossref] [PubMed]
  • 25. Martínek P, Grossmann P, Hes O, Bouda J, Eret v, frizzell N, et al. Genetic testing of leiomyoma tissue in women younger than 30 years old might pro- vide an effective screening approach for the hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC). virchows Arch. 2015;467(2):185-91. [Crossref] [PubMed]
  • 26. Zhang L, Walsh Mf, Jairam S, Mandelker D, Zhong Y, Kemel Y, et al. fu- marate hydratase fH c.1431_1433dupAAA (p.Lys477dup) variant is not as- sociated with cancer including renal cell carcinoma. Hum Mutat. 2020;41(1):103-9. [Crossref] [PubMed] [PMC]
APA Kazancı F, Yüksel D, Ezgu F, ERDEM Ö, Onan M (2023). Variants of Fumarate Hydratase Gene in Uterine Disorders: A Clinical Trial. , 81 - 87. 10.5336/jcog.2022-94609
Chicago Kazancı Ferah,Yüksel Dilek,Ezgu Fatih Suheyl,ERDEM Özlem,Onan MEHMET ANIL Variants of Fumarate Hydratase Gene in Uterine Disorders: A Clinical Trial. (2023): 81 - 87. 10.5336/jcog.2022-94609
MLA Kazancı Ferah,Yüksel Dilek,Ezgu Fatih Suheyl,ERDEM Özlem,Onan MEHMET ANIL Variants of Fumarate Hydratase Gene in Uterine Disorders: A Clinical Trial. , 2023, ss.81 - 87. 10.5336/jcog.2022-94609
AMA Kazancı F,Yüksel D,Ezgu F,ERDEM Ö,Onan M Variants of Fumarate Hydratase Gene in Uterine Disorders: A Clinical Trial. . 2023; 81 - 87. 10.5336/jcog.2022-94609
Vancouver Kazancı F,Yüksel D,Ezgu F,ERDEM Ö,Onan M Variants of Fumarate Hydratase Gene in Uterine Disorders: A Clinical Trial. . 2023; 81 - 87. 10.5336/jcog.2022-94609
IEEE Kazancı F,Yüksel D,Ezgu F,ERDEM Ö,Onan M "Variants of Fumarate Hydratase Gene in Uterine Disorders: A Clinical Trial." , ss.81 - 87, 2023. 10.5336/jcog.2022-94609
ISNAD Kazancı, Ferah vd. "Variants of Fumarate Hydratase Gene in Uterine Disorders: A Clinical Trial". (2023), 81-87. https://doi.org/10.5336/jcog.2022-94609
APA Kazancı F, Yüksel D, Ezgu F, ERDEM Ö, Onan M (2023). Variants of Fumarate Hydratase Gene in Uterine Disorders: A Clinical Trial. Journal of Clinical Obstetrics & Gynecology, 33(2), 81 - 87. 10.5336/jcog.2022-94609
Chicago Kazancı Ferah,Yüksel Dilek,Ezgu Fatih Suheyl,ERDEM Özlem,Onan MEHMET ANIL Variants of Fumarate Hydratase Gene in Uterine Disorders: A Clinical Trial. Journal of Clinical Obstetrics & Gynecology 33, no.2 (2023): 81 - 87. 10.5336/jcog.2022-94609
MLA Kazancı Ferah,Yüksel Dilek,Ezgu Fatih Suheyl,ERDEM Özlem,Onan MEHMET ANIL Variants of Fumarate Hydratase Gene in Uterine Disorders: A Clinical Trial. Journal of Clinical Obstetrics & Gynecology, vol.33, no.2, 2023, ss.81 - 87. 10.5336/jcog.2022-94609
AMA Kazancı F,Yüksel D,Ezgu F,ERDEM Ö,Onan M Variants of Fumarate Hydratase Gene in Uterine Disorders: A Clinical Trial. Journal of Clinical Obstetrics & Gynecology. 2023; 33(2): 81 - 87. 10.5336/jcog.2022-94609
Vancouver Kazancı F,Yüksel D,Ezgu F,ERDEM Ö,Onan M Variants of Fumarate Hydratase Gene in Uterine Disorders: A Clinical Trial. Journal of Clinical Obstetrics & Gynecology. 2023; 33(2): 81 - 87. 10.5336/jcog.2022-94609
IEEE Kazancı F,Yüksel D,Ezgu F,ERDEM Ö,Onan M "Variants of Fumarate Hydratase Gene in Uterine Disorders: A Clinical Trial." Journal of Clinical Obstetrics & Gynecology, 33, ss.81 - 87, 2023. 10.5336/jcog.2022-94609
ISNAD Kazancı, Ferah vd. "Variants of Fumarate Hydratase Gene in Uterine Disorders: A Clinical Trial". Journal of Clinical Obstetrics & Gynecology 33/2 (2023), 81-87. https://doi.org/10.5336/jcog.2022-94609